Alto Neuroscience reports 2025 highlights — CANOPY Phase 3 PTSD trial on track for Q4 2026 data
Summary
Alto Neuroscience reported full-year 2025 financial results and business highlights, confirming the CANOPY Phase 3 trial for ALTO-300 in PTSD is on track with enrollment across 30 US sites and top-line data expected Q4 2026. The company also reported progress in their schizophrenia negative symptoms program (ALTO-100) and announced a new collaboration for EEG biomarker validation in ADHD. Total 2025 research spending increased 67% as multiple programs advanced simultaneously.
Why it matters
Alto managing three simultaneous EEG-guided psychiatric drug programs — PTSD, schizophrenia, and ADHD — while reporting 67% R&D spend increase demonstrates the platform scalability of their precision psychiatry approach. The Q4 2026 CANOPY data readout is the most anticipated precision psychiatry clinical event on the neurotech calendar.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial